Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells.
Mechanism of action
Monalizumab is a blocking antibody that prevents the inhibition of
CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting
simultaneously on innate and adaptive immunity, monalizumab may
re-establish a broad anti-tumor response.
